

ARTnet Research News Update

ENZA-p clinical trial results presented at ASCO GU




Figure 2: Overall survival
¹⁷⁷Lu=lutetium-177. HR=hazard ratio.

Lancet Oncology, 2025, published online

Congratulations to Prof. Louise Emmett, ENZA-p investigators and all 15 Australian ENZA-p sites for the recently presented overall survival data for the ENZA-p trial presented at ASCO GU on Friday 14/2/25. The ENZA-p trial was led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) in a collaboration between ANZUP, the NHMRC Clinical Trials Centre and Australasian Radiopharmaceutical Trials Network (ARTnet). This phase II randomised multicentre prospective study, conducted in men with high risk metastatic castration-resistant prostate cancer not previously treated with docetaxel or androgen receptor pathway inhibitors, demonstrated longer overall survival in the enzalutamide plus [¹⁷⁷Lu]Lu-PSMA-617 group than in the enzalutamide group. Quality of life scores in pain and fatigue were also improved in the combination arm. These promising results highlight the potential for combination therapies in men with metastatic prostate cancer to improve survival and symptom outcomes

Lancet Oncology manuscript link: [Overall survival and quality of life with \[¹⁷⁷Lu\]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer \(ENZA-p\): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial - The Lancet Oncology](#)

ANZUP Press Release: [New research findings from the ENZA-p study \(ANZUP 1901\), reveal a world-first combination treatment approach resulted in improvement in both survival and quality of life, for people living with a poor prognosis prostate cancer – ANZUP](#)